Dr. Jaume Bosch has been recognized for his work in the field of hepatology and specifically in the analysis of portal hypertension and hemodynamic alterations associated with liver disease. Portal hypertension is the leading cause of death and liver transplantation in cirrhosis. The contributions of Dr. Bosch have uncovered new therapeutic targets that have been incorporated into clinical practice, reducing the mortality associated with this disease from 50% to under 20% in the last two decades. His laboratory, internationally renowned, has trained many scientists around the world and has furthered the translational research and hepatology in general in Spain. He is currently President of the Spanish Association for Study of the Liver. "His research stands out for its innovation. He has created or modified treatment regimens and therapeutic approaches and opened new lines of research", says the director of the Lilly Foundation, José Antonio Sacristán.
Clínic Barcelona
Clínic Barcelona
March 22 2013
Dr. Jaume Bosch, receives the Lilly Foundation Biomedical Research 2013 Award in the category of clinical research
The Lilly Foundation has awarded the Biomedical Research Awards 2013 in the categories of preclinical and clinical research, respectively, to Dr. Andrés Moya, scientific director of the Centre Superior d'Investigació en Salut Pública de la Conselleria de Sanitat de la Generalitat Valenciana (CSISP-FISABIO), and Dr. Jaume Bosch, scientific director of CIBER of Hepatic and Digestive Diseases (CIBERehd) and professor of medicine at the Hospital Clínic - IDIBAPS of Barcelona. These awards, endowed with an amount of € 40,000 each, recognize excellence scientific career of researchers who have contributed to the development of Biomedicine and Health Sciences in Spain.
